Kura Oncology (KURA) Stock: Buy, Sell, or Hold?
$7.57
+0.00 (+0.00%)
▲
5d:
-23.38%
30d:
-27.18%
90d:
-23.84%
QUANTITATIVE VERDICT
WAIT
LOW Confidence (95%)
Quality Score
60/100
Position
OVERSOLD
30-Day Fair Range
$8.46 – $10.71
Position: OVERSOLD
Forward P/E & Valuation
-3.2x
Next 12M consensus est.
Wall Street Target
$31.85
+320.7% upside
Options IV & Volume
HIGH Vol
HIGH volume confirmation
Support / Resistance
$6.75 / $10.96
Trend: Uptrend
Executive Thesis & Bottom Line
Forward Earnings Fair Value & Price Prediction →
⏸️ WAIT FOR STABILIZATION: KURA is down 23.4% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
Get Alerted When KURA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
In-depth Analysis How we analyze
Valuation Analysis: KURA is currently trading at $7.57, which is considered oversold relative to its 30-day fair value range of $8.46 to $10.71.
Technical Outlook: Technically, KURA is in a uptrend. Immediate support is located at $6.75, while resistance sits at $10.96.
Market Sentiment: KURA scores 63/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $31.85 (+320.7%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, KURA is in a uptrend. Immediate support is located at $6.75, while resistance sits at $10.96.
Market Sentiment: KURA scores 63/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $31.85 (+320.7%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$8.46 -
$10.71
Company Quality Score
60/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
94.7%
Trading Range & Key Levels
30-Day Trading Range
$8.46 -
$10.71
Current vs Trading Range
OVERSOLD
Support Level
$6.75
Resistance Level
$10.96
Current Trend
Uptrend
Technical data as of
Nov 10, 2026
Quantitative Signal Breakdown
- BULLISH: Price oversold vs 30-day range
- BULLISH: Strong technical setup (63/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 320.7% below Wall St target ($31.85)
- BULLISH: Bottoming setup score 63/100 — corrected, stabilizing, and turning up
- WARNING: Recommendation downgraded due to -23.4% 5-day decline - wait for stabilization
Fundamental Context
Forward P/E (Next Year Est.)
-3.23
Wall Street Target
$31.85
(+320.7%)
Revenue Growth (YoY)
36.5%
Share KURA Analysis
Share this live KURA analysis (with rich preview card) to Reddit, StockTwits, X, or embed the chart on your blog.
bloggers & journalists: you are free to use our charts with attribution.Reddit & Retail Trader Sentiment (KURA)
Bullish
6 Retail Mentions
Reddit / WSB Comments
1
Bearish
StockTwits Volume
5 msgs
24h retail stream
Last Tracked
Nov 11, 2026
Daily AI digest
AI Retail Discussion Summary:
Kura Oncology reported a loss in Q3 but beat revenue estimates, with revenue coming in at $22.8 million. The company also announced positive clinical trial data for its lead drug, tipifarnib.
Key Retail Themes:
Positive clinical trial data for tipifarnib
Revenue beat in Q3
Aggregated from r/wallstreetbets, r/stocks & StockTwits streams.
View All Trending Reddit & WSB Stocks →
Last updated: November 11, 2026 5:35 AM ET
Data refreshes hourly during market hours. Next update: 6:35 AM
Data refreshes hourly during market hours. Next update: 6:35 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is KURA showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
CYTK
Cytokinetics Inc |
STRONG BUY
22 analysts |
$107 | 62 BUY |
|
INSM
Insmed Inc |
STRONG BUY
24 analysts |
$194 | 41 HOLD |
|
MDGL
Madrigal Pharmaceuticals… |
STRONG BUY
19 analysts |
$689 | 55 HOLD |
|
RZLT
Rezolute Inc |
STRONG BUY
11 analysts |
$10 | 72 BUY |
|
IMNM
Immunome Inc |
STRONG BUY
17 analysts |
$35 | 47 HOLD |
Explore More Analysis & Live Quant Tools
Part A: Deep-Dive KURA Research Pages
